{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:15:25Z","timestamp":1778681725486,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["207499"],"award-info":[{"award-number":["207499"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The phase 3 DREAMM-8 (NCT04484623) trial assessed belantamab mafodotin\u2009+\u2009pomalidomide\u2009+\u2009dexamethasone (BPd) vs bortezomib\u2009+\u2009Pd (PVd) in lenalidomide-exposed patients with relapsed\/refractory multiple myeloma (RRMM) and \u2265\u20091 prior therapy. Here, we present findings from Japanese patients (data cutoff: 27-May-24). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), duration of response (DoR), and safety. Overall, 21 patients were randomized 1:1 to BPd (N\u2009=\u200910) and PVd (N\u2009=\u200911). Median follow-up was 13.8\u00a0months (range 0.23\u201326.71). For BPd vs PVd, median PFS was not reached (NR; 95% CI 0.2\u2013NR) vs 14.8\u00a0months (95% CI 1.9\u2013NR; HR 0.53; 95% CI 0.1\u20132.8); ORR was 90% (9\/10) vs 73% (8\/11), including very good partial response or better in 70% (7\/10) vs 36% (4\/11); median DoR was NR vs 17.5\u00a0months. The safety profile was consistent with the global cohort. Ocular adverse events were more common with BPd vs PVd (90% [9\/10] vs 9% [1\/11]) and a majority were transient and reversible. While the sample size of this study is small, findings were aligned with the global cohort. BPd showed favorable efficacy compared with PVd, with a manageable safety profile in lenalidomide-exposed Japanese patients with RRMM.<\/jats:p>","DOI":"10.1007\/s12185-025-04150-6","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:20:51Z","timestamp":1767684051000},"page":"686-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trial"],"prefix":"10.1007","volume":"123","author":[{"given":"Kazutaka","family":"Sunami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeko","family":"Yonekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ianire Garrobo","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4950-8687","authenticated-orcid":false,"given":"Hitomi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"4150_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1182\/hematology.2024000581","volume":"2024","author":"SK Kumar","year":"2024","unstructured":"Kumar SK. What is the ideal approach-doublet, triplet, or quadruplet(s)? Hematol Am Soc Hematol Educ Program. 2024;2024:551\u201360.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"4150_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:309\u201322.","journal-title":"Ann Oncol"},{"key":"4150_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12185-019-02636-8","volume":"109","author":"S Iida","year":"2019","unstructured":"Iida S, Ishida T, Murakami H, Ozaki S, Abe M, Hata H, et al. JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). Int J Hematol. 2019;109:509\u201338.","journal-title":"Int J Hematol"},{"key":"4150_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396\u2013406.","journal-title":"Haematologica"},{"key":"4150_CR5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37:1228\u201363.","journal-title":"J Clin Oncol"},{"key":"4150_CR6","unstructured":"JSH practical guidelines for hematological malignancies, version 3.1. iii. Myeloma; 1. Multiple myeloma (MM). 2024 25 March 2025]; Available from: http:\/\/www.jshem.or.jp\/gui-hemali\/3_1_1.html"},{"key":"4150_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315932","volume":"20","author":"S Iida","year":"2025","unstructured":"Iida S, Yasutomi Y, Samyshkin Y, Chen YC, Chen CC, Lee WS, et al. Characteristics and treatment patterns in patients with multiple myeloma in Japan: a retrospective cohort analysis. PLoS ONE. 2025;20:e0315932.","journal-title":"PLoS ONE"},{"key":"4150_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/bjh.19627","volume":"205","author":"MA Hartley-Brown","year":"2024","unstructured":"Hartley-Brown MA, Weisel K, Bitetti J, Carter JA, McNamara S, Purser M, et al. Multiple myeloma refractory to lenalidomide: a systematic literature review of trials and real-world evidence. Br J Haematol. 2024;205:780\u201397.","journal-title":"Br J Haematol"},{"key":"4150_CR9","doi-asserted-by":"publisher","first-page":"1550644","DOI":"10.3389\/fonc.2025.1550644","volume":"15","author":"F Gay","year":"2025","unstructured":"Gay F, Zamagni E, Cole CE, Scheid C, Hultcrantz M, Chorazy J, et al. Clinical outcomes associated with anti-CD38-based retreatment in relapsed\/refractory multiple myeloma: a systematic literature review. Front Oncol. 2025;15:1550644.","journal-title":"Front Oncol"},{"key":"4150_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005.","journal-title":"Leukemia"},{"key":"4150_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/curroncol28010063","volume":"28","author":"G Lassiter","year":"2021","unstructured":"Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, et al. Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects. Curr Oncol. 2021;28:640\u201360.","journal-title":"Curr Oncol"},{"key":"4150_CR12","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"4150_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112948","volume":"15","author":"S Mor\u00e8","year":"2023","unstructured":"Mor\u00e8 S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab mafodotin: from clinical trials data to real-life experiences. Cancers (Basel). 2023;15:2948.","journal-title":"Cancers (Basel)"},{"key":"4150_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med"},{"key":"4150_CR15","unstructured":"Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed\/refractory multiple myeloma. 2025 [30 April 2025]; Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma\/"},{"key":"4150_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391:408\u201321.","journal-title":"N Engl J Med"},{"key":"4150_CR17","unstructured":"Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed\/refractory multiple myeloma. 2025 [13 June 2025]; Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-japan\/"},{"key":"4150_CR18","unstructured":"Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed\/refractory multiple myeloma. 2025 [30 July 2025]; Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma\/"},{"key":"4150_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781\u201394.","journal-title":"Lancet Oncol"},{"key":"4150_CR20","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1182\/blood-2024-199282","volume":"144","author":"M Beksac","year":"2024","unstructured":"Beksac M, Gonzalez Garcia E, Delimpasi S, Robak P, Karunanithi K, De Arriba F, et al. Belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: a subset analysis in patients who have received 1 prior line of therapy including lenalidomide. Blood. 2024;144:4731.","journal-title":"Blood"},{"key":"4150_CR21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/jha2.743","volume":"4","author":"MS Raab","year":"2023","unstructured":"Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A. Difficult-to-treat patients with relapsed\/refractory multiple myeloma: a review of clinical trial results. EJHaem. 2023;4:1117\u201331.","journal-title":"EJHaem"},{"key":"4150_CR22","doi-asserted-by":"publisher","first-page":"LBA105","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA105","volume":"42","author":"S Trudel","year":"2024","unstructured":"Trudel S, Beksac M, Pour L, Delimpasi S, Quach H, Vorobyev VI, et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42:LBA105.","journal-title":"J Clin Oncol"},{"key":"4150_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14796694.2025.2460419","volume":"21","author":"Y Yasutomi","year":"2025","unstructured":"Yasutomi Y, Ribbands A, Luke E, McNamara S. Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey. Future Oncol. 2025;21:681\u201390.","journal-title":"Future Oncol"},{"key":"4150_CR24","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/S2152-2650(24)02315-2","volume":"24","author":"H Quach","year":"2024","unstructured":"Quach H, Dimopoulos M, Beksac M, Pour L, Delimpasi S, Vorobyev V, et al. Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study. Clin Lymphoma Myeloma Leuk. 2024;24:S273.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4150_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016949","author":"M-V Mateos","year":"2025","unstructured":"Mateos M-V, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 Trials. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025016949.","journal-title":"Blood Adv"},{"key":"4150_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","volume":"11","author":"S Lonial","year":"2021","unstructured":"Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021;11:103.","journal-title":"Blood Cancer J"},{"key":"4150_CR27","doi-asserted-by":"publisher","first-page":"300","DOI":"10.6004\/jadpro.2023.14.4.4","volume":"14","author":"R Lu","year":"2023","unstructured":"Lu R, Morphey A, Diaz F, Chen J, Razmandi A, Richards T. Management of ocular toxicity in patients receiving Belantamab mafodotin. J Adv Pract Oncol. 2023;14:300\u20136.","journal-title":"J Adv Pract Oncol"},{"key":"4150_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaf148","author":"K Sunami","year":"2025","unstructured":"Sunami K, Fujisaki T, Funaki T, Ichii M, Ito S, Matsumoto M, et al. Practical guidance on the clinical management of ocular adverse events associated with belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Recommendations from a Japanese expert panel. Jpn J Clin Oncol. 2025. https:\/\/doi.org\/10.1093\/jjco\/hyaf148.","journal-title":"Jpn J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04150-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:29:56Z","timestamp":1778678996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4150"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04150-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazutaka Sunami received honoraria from BMS, Janssen Pharmaceutical K.K., Pfizer, and Sanofi; received grants or contracts from Ono Pharmaceutical Co., BeiGene, AbbVie, Sanofi, BMS, GSK, Chugai Pharmaceutical Co. Ltd., Otsuka, Janssen Pharmaceutical K.K., Novartis Pharmaceuticals, Pfizer, Kyowa Kirin, Mitsubishi Tanabe, and Incyte. Hiroshi Handa received grants or contract from Johnson & Johnson, BMS, Sanofi, Pfizer, GSK, Ono Pharmaceutical Co.; received honoraria from Johnson & Johnson, BMS, and Pfizer. Michiko Ichii received honoraria from Sanofi, Takeda Pharmaceutical, Novartis Pharmaceuticals, Bristol Myers Squibb, Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., and Chugai Pharmaceutical Co. Ltd.; consulting fees from GSK. Takayuki Ikezoe received honoraria from Sanofi; support for attending meeting\/travel from Sanofi, BMS, Janssen Pharmaceutical K.K. Kazuhito Suzuki received consulting fees from GSK; honoraria from Janssen Pharmaceutical K.K., and Ono Pharmaceutical Co; Dr. Kazuhito Suzuki is an editor for International Journal of Hematology. Shigeki Ito is an editor for International Journal of Hematology; received honoraria from Johnson & Johnson and Sanofi; participated on an advisory board for GSK and Pfizer. Yusuke Yamaguchi, Taeko Yonekawa, Elisabet Manasanch, and Hitomi Kato are employed by GSK. Akira Endo, Ianire Garrobo Calleja, Eric Lewis, and Hirofumi Nakano are employed by GSK and hold financial equities in GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}